Abbvie Inc (ABBV) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Industry, else..
 
Abbvie Inc   (NYSE: ABBV)
 

Abbvie Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ABBV Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 10.32 % 14.14 % 10.18 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 2.44 % -1.07 % -2.46 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 10.68 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 2.53 % 2.69 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 5.95 % 7.52 % 8.67 % 13.63 %


ABBV's Growth Comparisons in III. Quarter 2026




Abbvie Inc 's 10.32% year on year Revenue increase in the third quarter 2026 to 17.40 billions, marks slow-down from Abbvie Inc 's growth trends, and competes unfavorably to the 14.14% rise in the Major Pharmaceutical Preparations industry, but beating the 10.18% improvement in the Healthcare sector. Comparing the third quarter sales, Abbvie Inc was trailing overall market not just the Major Pharmaceutical Preparations industry.

Comparing the company's Revenue to the second quarter results, sales were higher by 2.44% . On the yearly basis, average annual sales growth for Abbvie Inc is 5.95%, while S & P 500's including only Businesses with the third quarter 2026 earnings, average annual sales growth is 13.63% over the past five years.

ABBV Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
All other
-18.2 %
-
Immunology Skyrizi
30.89 %
-
Immunology Skyrizi United States
29.33 %
-
Immunology Skyrizi International
39.92 %
-
Immunology Rinvoq
23.34 %
-
Immunology Rinvoq United States
15.16 %
-
Immunology Rinvoq International
43.37 %
-
Immunology Humira
-38.63 %
-
Immunology Humira United States
-52.02 %
-
Immunology Humira International
-12.2 %
-
Neuroscience Vraylar
18.3 %
-
Neuroscience Vraylar United States
18.22 %
-
Neuroscience Vraylar International
50 %
-
Neuroscience Botox Therapeutic
16.51 %
-
Neuroscience Botox Therapeutic United States
16.46 %
-
Neuroscience Botox Therapeutic International
16.78 %
-
Neuroscience Ubrelvy
41.25 %
-
Neuroscience Ubrelvy United States
41.63 %
-
Neuroscience Ubrelvy International
28.57 %
-
Neuroscience Qulipta
53.37 %
-
Neuroscience Qulipta United States
45.35 %
-
Neuroscience Qulipta International
119.05 %
-
Neuroscience Vyalev
219.05 %
-
Neuroscience Vyalev United States
1383.33 %
-
Neuroscience Vyalev International
96.49 %
-
Neuroscience Other Neuroscience
-19.35 %
-
Neuroscience Other Neuroscience United States
-38.67 %
-
Neuroscience Other Neuroscience International
-1.25 %
-
Oncology Venclexta
15.79 %
-
Oncology Venclexta United States
9.29 %
-
Oncology Venclexta International
21.53 %
-
Oncology Imbruvica
-24.66 %
-
Oncology Imbruvica United States
-37.24 %
-
Oncology Imbruvica International
7.18 %
-
Oncology Elahere
10.61 %
-
Oncology Elahere United States
-3.03 %
-
Oncology Elahere International
171.43 %
-
Oncology Epkinly
62.75 %
-
Oncology Epkinly United States
41.67 %
-
Oncology Epkinly International
113.33 %
-
Oncology Other Oncology United States
-
-
Aesthetics Botox Cosmetic
20.14 %
-
Aesthetics Botox Cosmetic United States
25.76 %
-
Aesthetics Botox Cosmetic International
13.79 %
-
Aesthetics Juvederm Collection
0.43 %
-
Aesthetics Juvederm Collection United States
13.33 %
-
Aesthetics Juvederm Collection International
-5.77 %
-
Aesthetics Other Aesthetics
-9.21 %
-
Aesthetics Other Aesthetics United States
-8.15 %
-
Aesthetics Other Aesthetics International
-15.56 %
-
Other Key Products Mavyret
14.71 %
-
Other Key Products Mavyret United States
28.87 %
-
Other Key Products Mavyret International
2.44 %
-
Other Key Products Creon United States
1.69 %
-
Other Key Products Linzess
91.22 %
-
Other Key Products Linzess United States
95.68 %
-
Other Key Products Linzess International
22.22 %
-
Total
12.43 %
-


Growth Rates of ABBV's Income in the third quarter 2026


ABBV Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) 229.15 % 4.19 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) -2.57 % -23.95 % -12.21 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) 134.85 % 30.81 % 30.98 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) 25.86 % -2.24 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change 5.82 % 14.12 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) 2143.62 % -16.85 % -38.86 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) 16.65 % -26.31 % -63.27 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) 331.98 % 6.33 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) 63.81 % -9.97 % -4.67 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change -1.74 % 14.58 % 8.91 % -28.64 %

ABBV Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) 2143.62 % -17.47 % -39.2 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) 16.65 % 21.94 % 11.78 % 27.07 %
Y / Y Net Income Change (Q3 TTM) 331.98 % 5.05 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) 63.81 % -10.2 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth -1.74 % 14.16 % 9.09 % 23.95 %

ABBV's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) 2280 % -31.09 % -38.86 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) 16.67 % -35.27 % -63.27 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) 341.67 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) 64.23 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth -2.79 % -0.46 % 8.91 % -28.64 %



ABBV EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) 2270 % -31.6 % -39.2 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) 16.75 % 7.1 % 11.78 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) 64.12 % 0.05 % 10.63 % 4.93 %
EPS Net 5 Year Avg. Change -2.8 % 14.16 % 9.09 % 23.95 %



Despite the -31.6% decline in Major Pharmaceutical Preparations industry, Abbvie Inc showed impressive surge in EPS in the third quarter by 2270% from the same quarter a year ago, to $2.37, Healthcare sector dropped -39.2%. Despite modest earnings per share in the Major Pharmaceutical Preparations industry and ind the Healthcare sector, Abbvie Inc reported above average market earnings per share growth.

The bottom-line improved by 16.75% from the second quarter. Looking into annual income per share rise of -2.8%, and S & P 500's average yearly income per share growth is 23.95% over the five years, including only Businesses with the third quarter 2026 earnings reports. Abbvie Inc grew less than the market.

ABBV Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) 9.97 % 25.56 % 44.26 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) 134.59 % -29.98 % -42.65 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) -4.13 % 12.34 % 19.33 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) 3.64 % 3.59 % 5.88 % 15.75 %
Free Cash Flow 5 Year Avg. Change 1.19 % 0.88 % 0.41 % 1.8 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -21 % 18.43 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) -6.52 % -21.14 % -19.32 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) 3.49 % 15.46 % 9.34 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) -6.17 % 1.83 % 0.99 % 23.05 %
Capital Expenditures 5 Year Avg. Change 8.75 % 7.88 % 8.63 % 14.2 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.